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Abstract 
Background: MicroRNAs (miRNAs) can bind to the 3'-untranslated regions (UTRs) of messenger RNAs, where 
they interfere with translation and thereby regulate cell differentiation, apoptosis, and tumorigenesis. Genetic 
polymorphisms in the 3'-UTRs targeted by miRNAs alter the strength of miRNA binding in a manner that affects 
the behavior of individual miRNAs. The histone methyltransferase SET8 has been reported to be a regulator of 
Tumor Protein 53 (TP53) methylation, a tumor suppressor gene, and regulate genomic stability. Furthermore, an 
association between the TP53 and Prostate Cancer has been reported in several studies. The present study aimed 
to evaluate whether (rs16917496) polymorphism at the miR-502 binding site in the 3' untranslated region of the 
histone methyltransferase SET8 is associated with the expression of this gene in Benign Prostatic Hyperplasia 
(BPH) and prostate cancer (PCa) patients. 
Materials and Methods: We examined whether an rs16917496 polymorphism is associated with the risk of PCa 
and BPH in the Iranian population. This case-control study included 40 patients with pathologically confirmed 
PCa, 59 patients with BPH, and 45 controls. The rs16917496 polymorphism was determined using a restriction 
fragment length polymorphism (RFLP). 
Results: We found significant association of rs16917496 in benign prostatic hyperplasia (BPH). The most 
frequent genotype in the control, prostate cancer, and BPH groups were TT, TC, and CC, respectively. 
Conclusion: This study demonstrates that the heterozygote genotype of the SET8 polymorphism in the mir-502 
gene could be considered a risk factor for the emergence of prostate cancer. 
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Introduction 
Prostate cancer (PCa) is a common solid malignancy 
and has high mortality rate1. Not only does it represent 
a major factor in male morbidity and mortality, but it 
also places an economic burden on the population2. 
The significant problem of PCa is the development and 
acquisition of the castrate resistant prostate cancer 
(CRPC) phenotype which finally leads to the 
development of skeletal metastasis (mCRPC), at which 
point it becomes an incurable disorder1,3. Therefore, 
research studies are underway to understand the 
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molecular basis of the mCRPC so that novel 
therapeutic strategies can be designed. To that end, 
many novel molecules are being trialed and assayed, 
among which microRNAs (miRNAs) are becoming an 
attractive area of investigation4,5. Another area of 
concern is Benign Prostatic Hyperplasia (BPH) that is 
one of the most common mankind disease6. 
MicroRNAs (miRNAs) with ~22 nucleotides RNA 
length act as posttranscriptional regulators of mRNA 
expression level by bounding to the “seed region”7 of 
2–8 nucleotides in the 3′ untranslated region (UTR) of 
mRNAs8,9. A perfect complement between the 
miRNA and its target mRNA sequence leads a 
reduction in protein levels due to RNA silencing10. 
Additionally, research results have indicated the 
evidence of the how the role of single nucleotide 
polymorphisms (SNPs) in the 3′ UTR can alter the 
targeted genes’ expression and consequently affect an 
individual’s cancer risk6,11,12. PR-Set7/Set8/KMT5a 
(SET8), located on the chromosome 12q24.31, is 
regulated by the miR-502 through the binding site of 
3′ UTR of SET8 mRNA, that encodes the histone H4 
lysine 20 monomethyltransferase which is implicated 
in normal cell cycle progression13. Also, human 
PrSet7 interacts directly with the DNA replication 
factor PCNA and depicts specific effects at origins of 
replication; SET8 depletion results in cells 
accumulation in S phase with increased DNA damage. 
Furthermore, the unsuitable SET8 expression also 
causes S phase defects and increased DNA damage14. 
Recent studies have revealed that the SET8 function 
was vital for the p53BP1 recruitment during the DNA 
double-strands breaking response. Moreover, SET8 
could increase the metastasis capacity of a cancer cell 
by promoting epithelial-mesenchymal transition15. It 
also mediates the monomethylation of p53/TP53 at 
Lys-382, causing repression of the p53/TP53-target 
genes. Recent studies have proposed that SET8 may 
have a link with carcinogenesis and cancer 
progression7,16,17. 
In addition, Previous studies show that SNP 
rs16917496-T/C located in the 3ʹUTR of the SET8 
mRNA was associated with the risk of the early onset 
of breast cancer, and this SNP region was foretold as 
a potential binding site of miR-50217,18. This SNP was 
afterward shown by others to be a susceptibility factor 
for some cancers, such as epithelial ovarian cancer and 
cervical cancer17. This broad spectrum of association 
proposes that this SNP is a robust genetic regulatory 
factor fundamental to cells. Nevertheless, the role of the 
SET8 3ʹ-UTR SNP in PCa prognosis has remained 
unknown and has not been reported, which is the main 
motivation of this survey17,19. In this study, we 
genotyped rs16917496 in Pca and BPH patients in a 
case-control study to assess its relationships to cancer 
risk and outcome. 
Methods 
Patients and controls: The 40-PCa and 59 BPH cases 
were collected from the Urology Center of Labafinejad 
Hospital, Tehran, Iran. This study included patients 
with newly diagnosed and histologically confirmed 
PCa and BPH. The 44 control samples of genetically 
unrelated men were collected during the same time. 
Control samples were selected based on a normal result 
of DRE (Digital Rectal Examination), and prostate 
specific antigen (PSA) levels less than four ng/milt. The 
criteria for selecting participants in the study included a 
diagnosis by a urologist and having no sign of other 
genetic or congenital disease or genital malformations. 
The ages ranged from 50 to 80 for all the samples. 
Peripheral blood samples from patient and control 
groups were taken using Venoject tubes containing 
EDTA (0.5 M). DNA samples were extracted using 
DNA extraction kits according to the manufacturer’s 
protocol (Qiagen, Valencia, California). 
Genotyping of rs16917496 polymorphisms: The 
SET8 3'UTR was analyzed for rs16917496 
polymorphisms using a restriction fragment length 
polymorphism (RFLP) for both case and control 
groups. The amplification conditions were: 95°C for 2 
min, 35 cycles of 95°C for 30 s, 59°C for 30 s, and 72°C 
for 45 s, and a final extension step at 72°C for 5 min. 
The primers on the miR-502 binding site were 5ʹ- 
GGCCTCACGACGGTGCTAC -3ʹ and 5ʹ- 
GTTCCCCAGGAGGATGCTTAC-3ʹ. A 308-bp DNA 
fragment was produced in this process, and then 
digested the DNA produced by SWAI (New England 
BioLabs, Inc.) overnight at 25°C. Allele T produced 
two bands including 149-bp and 159-bp, TC 
heterozygote produces three bands (149-bp, 159-bp, 
and 308-bp) and allele C lacks the SWAI restriction site 
and only produced a 308-bp band. 
Statistical analysis: All SNPs data were evaluated for 
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the Hardy-Weinberg equilibrium. The unprocessed 
data were analyzed with SNPStats software, T-test, 
chi-square and SPSS software (version 20.0). An 
association between each of the genotypes and 
prostate cancer risk was assessed by calculating a P-
value with 95% confidence intervals. A P-value<0.05 
was considered significant. 
Bioinformatic miRNA target prediction and 
analysis: The miRWalk 2.0 database was used to 
predict the potential target genes for miR-502, which 
combines the information with a comparison of 
binding sites resulting from other three existing 
miRNA-target prediction programs: miRNAMap, 
Targetscan6.2, miRanda-rel2010. 
Results 
We found significant associations of rs16917496 [OR 
5.8; 95% CI 1.30-26.51; p 0.001 < 0.05] and [OR 5.13; 
95% CI 0.92-28.57; p 0.001 < 0.05] in BPH with the 
risk of PCa and BPH in our population, respectively 
(Table 1). The phenotype data and frequency 
distribution of case groups are classified as shown in 
(Table 1). The results of the rs16917496 genotype 
analysis revealed the highest frequency of the TT 
genotype in the control group, and the highest 
frequency of the CT genotype in the both PCa and BPH 
samples. Higher frequency of C allele was in the BPH 
cases (n=59) compared with controls. However, the 
prostate cancer patients showed the same frequency of 
C allele as the healthy population (Table 2). We 
performed a Hardy–Weinberg equilibrium (HWE) test 
for studied polymorphism (rs16917496) in the three 
group-studied populations where the genotypic 
distributions of this polymorphism showed a p-value 
less than 0.05 considered in the H-W equilibrium. 
However, the rs16917496 revealed a significant p-value 
in the PCa and BPH groups patients, indicating a 
deviation from (HWE; Table 2). To determine the 
correlation between rs16917496 polymorphism with 
the incidence of PCa and BPH, genotypic information 
from the three groups of "control / PCa," " PCa / BPH" 
and " BPH / control " was used (Table 1). A comparison 
between the three groups shows that the genotype CT 
in Iranian population has a strong correlation with the 
incidence rate of PCa (OR = 6.19, CI = 1.99-19.28) and 
BPH (OR = 4.52, CI = 1.83-11.18). Both the control/ 
PCa and control / BPH groups revealed a significant p 
value. On the contrary, the p value PCa / BPH was not 
significant (Table 1). 
Table 1: Correlation analysis of rs16917496 polymorphism with prostate cancer and BPH disease in the Iranian 
population. 
Groups  Genotype OR (CI 95%) p value 
Control-Prostate Cancer TT 1.00  
0.0021 CT 6.19 (1.99-19.28) 
CC 5.88 (1.30-26.51) 
BPH-Prostate Cancer TT 1.00  
0.12 CT 1.37 (0.43-4.36) 
CC 5.13 (0.92-28.57) 
Control-BPH TT 1.00  
0.0018 CT 4.52 (1.83-11.18) 
CC 1.15 (0.23-5.71) 
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Discussion 
In the present study, we investigated the association 
between rs16917496 polymorphisms in the SET8 
gene with Prostate cancer disease and BPH in the 
Iranian population. We found a significant higher 
frequency T allele in both the control/ prostate cancer 
and control/ BPH. However, the similar frequency rate 
of the T allele in our studied patients with PCa might 
be a result of having a smaller number of samples of 
PCa compared to BPH and healthy subjects (Table 2). 
The results of the allele frequency of the rs16917496 
polymorphism in our population indicate that the C 
allele is less common compared to other populations 
in previous studies19,20. We found a strong association 
between the heterozygous (CT) genotype of the 
rs16917496 variant and risk of BPH and PCa in our 
population; however, in the control group, the TT 
genotype had higher frequency (Table 1). The results 
of the analysis of the polymorphism rs16917496 
genotype and allele frequencies in our groups indicate 
that despite the fact that the T allele could reduce the 
P53 gene expression, a high allele frequency in a 
healthy control population and population of BPH 
could also be indicated. It seems though the majority 
of the Iranian male population have an allele 
predisposed to cancer, may numerous genetic and 
environmental factors play an important role in the 
prevalence of PCa. Our results also showed a 
deviation from the Hardy-Weinberg equilibrium for 
this polymorphism in our patients. Although the 
rs16917496 polymorphism in the control group was in 
the Hardy-Weinberg equilibrium, the results from the 
patients with PCa and BPH show a deviation from the 
equilibrium. This might be a result of the role of this 
polymorphism in a susceptibility factor for cancer and 
BPH, such as age onset of cancer, tumor size, and blood 
PSA levels. On the contrary, the results of studies on 
PCa show inconsistent results. We can conclude that the 
differing results may be due to the low number of 
research samples on breast cancer. The problem can be 
solved by having more samples and examining more 
closely correlation of the rs16917496 polymorphism 
with PCa. Of course, different genetic and 
environmental factors in breast and PCa, as well as 
people with gender differences, can also be a reason for 
the differences observed in the results of the two 
studies. In 2012, a study on the relationship between the 
rs16917496 polymorphism and hepatocellular 
carcinoma (HCC) had shown that a C to T in the 
rs16917496 polymorphism could cause the loss of miR-
502 binding site and SET8. The inability to connect the 
miR-502 gene to SET8 can cause the enhanced 
expression of SET8 and ultimately reduce the P53 gene 
expression. The results of this study suggest that the 
miR-502 gene polymorphism junction in SET8 could 
affect the outcome of HCC. In fact, genotype CC in 
SET8 causes a lower expression of RNA and protein 
production, and that is associated with more survival 
time in patients. Univariate and multivariate analyses 
suggest that single nucleotide polymorphisms at the 
junction of miRNA 502 can be used as a diagnostic 
factor in patients with HCC20. 
Conclusion 
Our findings suggest the rs16917496 polymorphisms in 
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Prostate cancer 0.52 0.48 0.18 0.12 0.7 0.025 
BPH 0.43 0.57 0.05 0.19 0.76 <0.0001 
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SET8 3'UTR may harbor a susceptibility to PCa and 
BPH. Our findings may contribute to provide new 
insight into the molecular genetics of PCa and BPH. 
In addition, the observed SRD5A2 mutations indicate 
this gene is one of the most effective causes of PCa 
that need to be studied in other populations with larger 
sample size. Further investigations with diverse 
ethnicities and larger sample sizes are required to 
verify these results. 
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